Can-Fite BioPharma Ltd. (TLV: CANF)

Market Cap	51.21M
Revenue (ttm)	2.51M
Net Income (ttm)	-27.75M
Shares Out	1.83B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,312,583
Open	2.900
Previous Close	2.800
Day's Range	2.800 - 2.900
52-Week Range	2.500 - 5.600
Beta	0.65
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 8
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: CANF

Financial Performance

In 2023, Can-Fite BioPharma's revenue was $743,000, a decrease of -8.27% compared to the previous year's $810,000. Losses were -$7.63 million, -24.96% less than in 2022.

Financial numbers in USD